Investigation of Visual System Involvement in Spinocerebellar Ataxia Type 14.

"Conflict of Interest TI reports no conflict of interest. EK is a cofounder, shareholder, and CEO of NOCTURNE. TO reports no conflict of interest. ME reports grants from Bayer and fees paid to the Charité from Bayer, Boehringer Ingelheim, BMS/Pfizer, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, and Novartis, all outside the submitted work. TK receives/has received research support from the Deutsche Forschungsgemeinschaft (DFG), the Bundesministerium für Bildung und Forschung (BMBF), the Bundesministerium für Gesundheit (BMG), the Robert Bosch Foundation, the European Union (EU), and the National Institutes of Health (NIH). He has received consulting fees from Biohaven and UBC. He has received a speaker honorarium from Novartis. JS reports no conflict of interest. AUB is a cofounder and shareholder of Motognosis and Nocturne. He is named as an inventor on several patent applications regarding MS serum biomarkers, OCT image analysis, and perceptive visual computing. FP reports research and travel grants and speaker honoraria from Bayer, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Novartis, MedImmune, Biogen Idec, Alexion, Chugai, Shire and is a member of the steering committee of the OCTIMS study (Novartis), is a shareholder of Nocturne GmbH, unrelated to this work, and is named as an inventor on several OCT-based patent applications, unrelated to this work. MM reports no conflict of interest. SD obtained project funding for unrelated projects from Actelion and Teva and travel reimbursement from Actelion. TSH reports research and travel grants and speaker honoraria from Roelke pharma, Roche, Celgene, and Biogen, all unrelated to this work. HZ received research grants from Novartis, unrelated to this study."

"Funding Information Open Access funding provided by Projekt DEAL."